Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
The abstract details the results from a study analyzing real-world data to determine the prevalence of LEMS diagnoses among patients with SCLC in
Poster Session: P2.31 - Global Health, Health Services, and Health Economics – Real World Data
Title: Lambert-Eaton Myasthenic Syndrome is Underrecognized in Small Cell Lung Cancer: An Analysis of Real-World Data
“The results from the study have brought to light significant insights into the relationship between small-cell lung cancer and
Learn more about #WCLC23 here: https://wclc2023.iaslc.org/
About Catalyst Pharmaceuticals
With exceptional patient focus, Catalyst is committed to developing and commercializing innovative first-in-class medicines that address rare neurological and epileptic diseases. Catalyst’s flagship U.S. commercial product is FIRDAPSE® (amifampridine) Tablets 10 mg, approved for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS") for adults and for children ages six to seventeen. In January 2023, Catalyst acquired the U.S. commercial rights to FYCOMPA® (perampanel) CIII, a prescription medicine approved in people with epilepsy aged four and older alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures and with other medicines to treat primary generalized tonic-clonic seizures for people with epilepsy aged 12 and older. Further, Canada’s national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. Further, on July 18, 2023, Catalyst acquired an exclusive license for North America for vamorolone, a promising best-in-class dissociative anti-inflammatory steroid treatment for Duchenne Muscular Dystrophy. Vamorolone has received FDA Orphan Drug and Fast Track designations and has been granted a PDUFA action date of October 26, 2023.
For more information about Catalyst Pharmaceuticals, Inc., visit the Company’s website at: www.catalystpharma.com. For the Full Prescribing and Safety Information for FIRDAPSE®, please visit www.firdapse.com. For the Full Prescribing Information for FYCOMPA®, please visit www.fycompa.com.
American Cancer Society. Key Statistics for Lung Cancer. 2023. https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html
- Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Nat Rev Dis Primers 2021; 7(1):
- Titulaer MJ, Maddison P, Sont JK, et al. J Clin Oncol 2011; 29: 902–08.
- Wirtz PW, Lang B, Graus F, et al. J Neuroimmunol 2005; 164(1-2): 161-5.
- Gozzard P, Woodhall M, Chapman C, et al. Neurology 2015; 85(3): 235-9.
- Payne M, Bradbury P, Lang B, et al. J Thorac Oncol 2010; 5(1): 34-8.
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2022 and its other filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Mary Coleman Catalyst Pharmaceuticals, Inc.(305) 420-3200 email@example.com Media Contact David Schull Russo Partners(858) 717-2310 firstname.lastname@example.org
Source: Catalyst Pharmaceuticals, Inc.